Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Leases (2022 - 2025)

Inhibikase Therapeutics (IKT) has 4 years of Leases data on record, last reported at $34918.0 in Q2 2025.

  • On a quarterly basis, Leases fell 78.68% to $34918.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $34918.0, a 78.68% decrease, with the full-year FY2024 number at $101437.0, down 54.35% from a year prior.
  • Leases reached $34918.0 in Q2 2025 per IKT's latest filing, down from $68719.0 in the prior quarter.
  • Over the last five years, Leases for IKT hit a ceiling of $353250.0 in Q3 2022 and a floor of $34918.0 in Q2 2025.
  • A 4-year average of $202497.2 and a median of $207843.5 in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: fell 29.2% in 2023, then plummeted 78.68% in 2025.
  • Tracing IKT's Leases over 4 years: stood at $328643.0 in 2022, then crashed by 32.38% to $222227.0 in 2023, then plummeted by 54.35% to $101437.0 in 2024, then plummeted by 65.58% to $34918.0 in 2025.
  • Business Quant data shows Leases for IKT at $34918.0 in Q2 2025, $68719.0 in Q1 2025, and $101437.0 in Q4 2024.